Bausch Health closes Wuhan Shibo acquisition

Executive Summary

• Bausch Health’s aesthetics division, Solta Medical, completed the acquisition of Wuhan Shibo Zhenmei Technology Co. Ltd., the longtime Chinese distribution partner for its Thermage FLX and other aesthetic devices.
• Effective December 1 2025, Shibo becomes a wholly‑owned subsidiary of Solta Medical in China, giving Solta direct control over distribution and expanding its market presence.
• The deal is positioned to accelerate revenue growth and market share in the rapidly expanding Chinese aesthetics market.

Key Details

• Acquirer: Solta Medical, the global aesthetic business of Bausch Health Companies Inc.
• Target: Wuhan Shibo Zhenmei Technology Co. Ltd., operating as the “Shibo Group,” a private distributor of medical beauty products based in Wuhan, Hubei, China.
• Transaction Structure: 100 % equity acquisition; Shibo becomes a wholly‑owned subsidiary of Solta Medical.
• Effective Date: December 1 2025.
• Products Affected: Full responsibility for distribution of Solta’s Thermage FLX and other aesthetic devices in China.
• Strategic Rationale: Leverages an existing, decade‑long distribution network and local market knowledge to instantly access a large customer base, improve service speed, and capture growing demand for aesthetics treatments.
• Management Comments:
• Thomas J. Appio (CEO, Bausch Health) highlighted expanded geographic reach, market scale, and anticipated revenue growth.
• Jiny Kim (SVP, Solta Medical) noted the integration will enhance innovation and customer service.
• Belinda Bao (VP & GM, Solta China) emphasized stronger positioning as a growth driver for Bausch Health in China.

Notable Quotes

• “This acquisition expands Solta Medical's geographical reach and market scale in China… to drive future revenue and market share growth.” – Thomas J. Appio, CEO, Bausch Health
• “Integrating their team into Solta Medical allows us to build on that trust and deliver even greater value‑accelerating innovation by being closer to our customers.” – Jiny Kim, Senior Vice‑President, Solta Medical

Materiality Assessment: Material – Positive (the acquisition is expected to materially enhance Solta Medical’s market position and revenue potential in China).